The FDA joined Massachusetts officials in a surprise inspection of an unnamed pharmacy similar to the New England Compounding Center, which was tied to a national fungal meningitis outbreak. Cease-and-desist orders have been issued to at least four drug compounders since the start of the surprise inspections.

Related Summaries